Allarity Therapeutics Announces Reverse Stock Split of Common Stock
24. März 2023 06:00 ET
|
Allarity Therapeutics, Inc.
Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24, 2023 — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”),...
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
20. März 2023 06:00 ET
|
Allarity Therapeutics, Inc.
Company anticipates that the combination of pan-TKI dovitinib and PARP inhibitor stenoparib may generate synergistic anti-cancer activity Program initiation marks key milestone in Allarity’s...
Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
20. Januar 2023 16:01 ET
|
Allarity Therapeutics, Inc.
Press release Boston, MA U.S.A. (January 20, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together...
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
01. Dezember 2022 16:25 ET
|
Allarity Therapeutics, Inc.
PRESS RELEASE Boston, MA U.S.A. (December 1, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together...
Allarity Therapeutics Reports Third Quarter 2022 Financial Results
15. November 2022 16:01 ET
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
07. November 2022 18:15 ET
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (November 7, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
11. Oktober 2022 16:05 ET
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (October 11, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors
26. September 2022 06:00 ET
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (September 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology...
Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference
16. September 2022 06:00 ET
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (September 16, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology...
Allarity Therapeutics Announces Appointment of New Auditor
12. September 2022 16:10 ET
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (September 12, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel...